Cetuximab에 의한 아나필락시스를 보인 환자에서 성공적인 탈감작 적용 1예
Successful rapid desensitization for cetuximab-induced anaphylaxis
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Cetuximab, a chimeric mouse-human immunoglobulin, is an antiepidermal growth factor receptor monoclonal antibody. It has been approved by the U.S. Food and Drug Administration for the treatment of metastatic colorectal and head/neck cancer, but can cause fatal hypersensitivity reactions in some patients. A 66-year-old male with metastatic sigmoid cancer had cetuximab-induced anaphylaxis when the first dose of cetuximab was administered. Cetuximab was safely readministered for another 15 cycles based on the rapid desensitization protocol. We experienced a case of cetuximab-induced anaphylaxis on the first exposure which was successfully managed by rapid desensitization.
Abstract
Cetuximab, a chimeric mouse-human immunoglobulin, is an antiepidermal growth factor receptor monoclonal antibody. It has been approved by the U.S. Food and Drug Administration for the treatment of metastatic colorectal and head/neck cancer, but can cause fatal hypersensitivity reactions in some patients. A 66-year-old male with metastatic sigmoid cancer had cetuximab-induced anaphylaxis when the first dose of cetuximab was administered. Cetuximab was safely readministered for another 15 cycles based on the rapid desensitization protocol. We experienced a case of cetuximab-induced anaphylaxis on the first exposure which was successfully managed by rapid desensitization.
참고문헌 (18)
- Sampson HA, "Second symposium on the definition and management of anaphylaxis: summary report--second National Institute of Allergy and Infectious Disease", Food Allergy and Anaphylaxis Network symposium, 2006, pp.47, 373~380
- Wood RA, "Anaphylaxis in America : the prevalence and characteristics of anaphylaxis in the United States", J Allergy Clin Immunol, 133, pp.461~467 (2014)
- 이서영, "항암제 과민반응에 대한 탈감작요법의 최신지견", Allergy Asthma & Respiratory Diseases, 1(4), pp.295~302 (2013), 대한 소아알레르기 호흡기학회
- Zanotti KM, "Prevention and management of antineoplastic-induced hypersensitivity reactions", Drug Saf, 24, pp.767~779 (2001)
- Jerath MR, "A desensitization protocol for the mAb cetuximab", J Allergy Clin Immunol, 123, pp.260~262 (2009)
- Castells MC, "Hypersensitivity reactions to chemotherapy : outcomes and safety of rapid desensitization in 413 cases", J Allergy Clin Immunol, 122, pp.574~580 (2008)
- Madrigal-Burgaleta R, "Hypersensitivity and desensitization to antineoplastic agents : outcomes of 189 procedures with a new short protocol and novel diagnostic tools assessment", Allergy, 68, pp.853~861 (2013)
- Graham J, "Fresh from the pipeline : cetuximab", Nat Rev Drug Discov, 3, pp.549~ (2004)
- Van Cutsem E, "Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer", N Engl J Med, 360, pp.1408~1417 (2009)
- Vermorken JB, "Platinum-based chemotherapy plus cetuximab in head and neck cancer", N Engl J Med, 359, pp.1116~1127 (2008)
- Kang SP, "Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer--identification, prevention, and management", J Support Oncol, 5, pp.451~457 (2007)
- Needle MN, "Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody", Semin oncol, 29(5 Suppl 14), pp.55~60 (2002)
- Chung CH, "Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose", N Engl J Med, 358, pp.1109~1117 (2008)
- Lee JH, "Delayed mammalian meat-induced anaphylaxis confirmed by skin test to cetuximab", J Dermatol, 40, pp.577~578 (2013)
- Naclerio R, "Immunologic observations during desensitization and maintenance of clinical tolerance to penicillin", J Allergy Clin Immunol, 71, pp.294~301 (1983)
- Kepley CL, "Antigen-induced reduction in mast cell and basophil functional responses due to reduced Syk protein levels", Int Arch Allergy Immunol, 138, pp.29~39 (2005)
- Castells M, "Hypersensitivity to antineoplastic agents : mechanisms and treatment with rapid desensitization", Cancer Immunol Immunother, 61, pp.1575~1584 (2012)
- Chung CH, "Managing premedications and the risk for reactions to infusional monoclonal antibody therapy", Oncologist, 13, pp.725~732 (2008)